All Photos(3)

Documents

C0737

Cilostazol

Name: Cilostazol
Brand: SIGMA

≥98% (HPLC), powder

Synonym(s):

6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone, OPC 13013, OPC 21, Pletaal

Sign Into View Organizational & Contract Pricing

All Photos(3)

About This Item

Empirical Formula (Hill Notation):

C₂₀H₂₇N₅O₂

CAS Number:

73963-72-1

Molecular Weight:

369.46

MDL number:

MFCD00866780

UNSPSC Code:

41106305

PubChem Substance ID:

24278291

NACRES:

NA.77

Assay

≥98% (HPLC)

form

powder

color

off-white

solubility

DMSO: 10 mg/mL, clear

originator

Otsuka Pharma

SMILES string

O=C1CCc2cc(OCCCCc3nnnn3C4CCCCC4)ccc2N1

InChI

1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)

InChI key

RRGUKTPIGVIEKM-UHFFFAOYSA-N

Gene Information

human ... PDE3A(5139) , PDE3B(5140)

Looking for similar products? Visit Product Comparison Guide

General description

Cilostazol prevents platelet aggregation and has vasodilatory properties. It is used to treat chronic arterial disease and intermittent claudication. Cilostazol has antiproliferative effects and improves the properties of prostacyclin. It regulates cell proliferation, stimulates cyclic adenosine monophosphate (cAMP) level and induces cyclic AMP-dependent protein kinase.

Application

Cilostazol has been used:

to reduce Madin–Darby cell line (MDCK) proliferation through c-Myc down-regulation
in the in vitro assessment of toxin delivery in T84 intestinal epithelial cells
to induce adenosine triphosphate (ATP) release in white adipocytes

Biochem/physiol Actions

Phosphodiesterase III (PDE3) inhibitor

Features and Benefits

This compound is a featured product for Cyclic Nucleotide research. Click here to discover more featured Cyclic Nucleotide products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Otsuka Pharma. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

GHS08

Signal Word

Warning

Hazard Statements

H361d

Precautionary Statements

P201 - P202 - P280 - P308 + P313 - P405 - P501

Hazard Classifications

Repr. 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial

Dawson DL, et al.

Circulation, 98(7), 678-686 (1998)

Cilostazol reduces proliferation through c-Myc down-regulation in MDCK cells

Munoz B, et al.

European Journal of Pharmacology, 616(1-3), 22-30 (2009)

Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease

Money SR, et al.

Journal of Vascular Surgery, 27(2), 267-275 (1998)

Molecular determinants of enterotoxigenic Escherichia coli heat-stable toxin secretion and delivery

Zhu Y, et al.

Infection and Immunity, 86(11), e00526-e00518 (2018)

Pannexin-1 mediated ATP release in adipocytes is sensitive to glucose and insulin and modulates lipolysis and macrophage migration

Tozzi M, et al.

bioRxiv, 380469-380469 (2018)

View All Related Papers